Showing results (1791-1800 of 3,157) with videos related to
Sort By:
Pageof 316
Neuro-Oncology|July 17, 2015
Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questionsSameer Agnihotri, Gelareh ZadehNeuro-Oncology|August 30, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy ConsortiumChetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, et al.Neuro-Oncology|August 10, 2016
Radiogenomics to characterize regional genetic heterogeneity in glioblastomaLeland S Hu, Shuluo Ning, Jennifer M Eschbacher, et al.Neuro-Oncology|July 3, 2015
Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based studyMirja Erika Gunn, Nea Malila, Tuire Lähdesmäki, et al.Neuro-Oncology|August 12, 2021
Multimodal platform for assessing drug distribution and response in clinical trialsBegoña G C Lopez, Ishwar N Kohale, Ziming Du, et al.Neuro-Oncology|May 28, 2020
Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrenceEkjot Kaur, Jyothi Nair, Atanu Ghorai, et al.Neuro-Oncology|September 1, 2021
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic ReviewSebastian Brandner, Alexandra McAleenan, Claire Kelly, et al.Neuro-Oncology|May 16, 2021
Histiocytosis and the nervous system: from diagnosis to targeted therapiesFleur Cohen Aubart, Ahmed Idbaih, Jean-François Emile, et al.Neuro-Oncology|August 11, 2022
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network studyAntoine Seyve, Caroline Dehais, Olivier Chinot, et al.Neuro-Oncology|May 16, 2020
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusionsAnna Luisa Di Stefano, Alberto Picca, Edouard Saragoussi, et al.Pageof 316